Achievements of the Science-based Venture Capitalist, Scott M. Rocklage

Scott M.Rocklage is a budding entrepreneur who is a strong proponent of measured risk-taking. In his venture as a life science-based venture capital firm, he believes in entrepreneurial ventures.

Dr. Rocklage attained his B.S. in Chemistry from California University, Berkeley and his Ph.D. in Chemistry from Massachusetts Institute of Technology (MIT). His research was conducted in the laboratory of the acclaimed Nobel Prize Winner of 2005, Richard R. Schrock.

Scott M. Rocklage, Ph.D. joined 5 A.M Ventures in the year 2003 as a Partner and eventually became a Managing Partner in 2004. Based in Boston Massachusetts, Scott has been reviewed in 100 peer-reviewed publications and invented or co-invented on more than 30 U.S. patents. Learn more about Scott Rocklage:  http://www.rennovia.com/team/scott-m-rocklage/ and http://5amventures.com/team/scott-m-rocklage-phd/

With healthcare management experience spanning over three decades coupled with responsibilities of strategic leadership in nature, Scott M Rocklage ensured that Drug Applications (Cubicin®, Teslascan®, and Omniscan™) were approved by the Food and Drug Administration (FDA). Through him, multiple drugs were entered into a variety of clinical trial programs.

Currently, he serves as the Board Chairman of Kinestral, Rennovia, and Cidara (NASDAQ: CDTX) as well as on the Boards of Pulmatrix (NASDAQ: PULM) and Epirus (NASDAQ: EPRS).

Dr. Rocklage has previously held various Research & Development positions at Salutar and Catalytica. He served as CEO and Chairman of Cubist Pharmaceuticals, CEO President and of Nycomed Salutar.

He was also a former Board Chairman of Novira (which was acquired by Johnson & Johnson Co.) and Relypsa (NASDAQ: RLYP). Formerly he was the Executive Chairman of Ilypsa (which was acquired by Amgen), Miikana (which was acquired by EntreMed), and finally Semprus (which was acquired by Teleflex).

Scott loves to work with entrepreneurs – mostly scientists, physicians or business executives to assist them shape their ideas and visions into potential medicines to treat unmet or existing medical needs.